Biopharma company Omeros (NSDQ:OMER) said that it closed a $68.3 million underwritten public offering last week, selling 3 million shares of its common stock at $22.75 apiece.
After deducting fees and other expenses, Omeros said it is slated to reel in $63.6 million from the offering. The company plans to use its newly-acquired funds to support R&D for its clinical-stage programs and for costs associated with BLA and NDA submissions.
Get the full story at our sister site, Drug Delivery Business News.
The post Omeros closes $68m public offering appeared first on MassDevice.
from MassDevice http://ift.tt/2vaTDhR
Cap comentari:
Publica un comentari a l'entrada